Panel of experts

scientists bringing deep expertise in all areas of life sciences

A group of scientists, deeply experienced in all areas of biomedicine and life sciences, has agreed to support the initiative of Rare Partners, making available their expertise and know-how on a non profit basis.

They act as high level consultants for the company and play an important role in designing the strategy of product development for the specific projects managed by Rare Partners.

Paolo Baroldi, MD

Giulio Cossu, MD

Francesco Dotta, MD

Pierangelo Geppetti, MD

Daniela Jabès, PhD

Gaetano Orsini, B.Sc.

Pierfausto Seneci, B.Sc.


Paolo Baroldi, MD

Paolo Baroldi, MD, PhD, has been serving as Senior Vice President of Clinical Development and Chief Medical Officer at Supernus, Inc. since January 2009.
From 2006 to 2009, he served as Senior Vice President and Chief Medical Officer at Vanda Pharmaceuticals.

From 2003 to 2006, Dr. Baroldi served as Vice President of Corporate Drug development and Chairman of the R&D Board at Chiesi Farmaceutici SpA. From 1998 to 2002 he was Global Head of Clinical Pharmacology at Novartis Pharma, responsible for all early development studies across eight different therapeutic areas.

Dr. Baroldi holds degrees in Medicine and Surgery (Universitas Studiorum Milan), Philosophy and History (Universitas Studiorum Milan) a PhD in Clinical Pharmacology (Universitas Studiorum Milan) and an Executive MBA from Harvard University.
Dr. Baroldi holds a contract professor position at Johns Hopkins University.

return to list


Giulio Cossu, MD

Giulio Cossu is Professor of Human Stem Cell Biology at University College since 2102. He was previously Director of the Division of Regenerative Medicine of San Raffaele Scientific Institute of Professor of Histology at the University of Milan. He received his MD degree from the University of Rome and has been work subsequently at the University of Pennsylvania, the University of Rome and the Institut Pasteur.

Giulio Cossu has been working for more than thirty years,  on the embryology and pathology of skeletal muscle, has carried out the first clinical trial with stem cells for Duchenne Muscular Dystrophy and has published more than 170 papers in peer-reviewed journals. He is EMBO member, Senior Editor of EMBO Molecular Medicine, member of the Cell Advanced Therapy  committee of EMA and panel meber (LS7) of ERC. He was president of the Italian Society of Cell Biology and is currently Co-President of the Luca Coscioni Association.

return to list


Francesco Dotta, MD

Francesco Dotta is President of Umberto Di Mario Research Foundation and Director of the Diabetes Unit at University of Siena, where he is Associate Professor of Endocrinology. He published more than 100 full papers in peer-reviewed journals.

His research is funded by several agencies including Juvenile Diabetes Research Foundation International, European Community, Italian Ministry of Health, Italian Ministry of Research, Tuscany Region.
The characterization of diabetes-associated islet autoimmune response and the identification of islet cell damage and regeneration phenomena represents the major focus in Dotta’s laboratory.
Above mentioned research lines contributed to:

  • the discovery of beta-cell enteroviral infection in a subset of type 1 diabetic patients
  • the observation that modulation of gut immune system through specific bacteria represent a potential strategy for beta-cell protection
  • the identification that human pancreatic islet precursors may be in vitro expanded and re-differentiated into insulin-producing cells.

return to list


Pierangelo Geppetti, MD

Pierangelo Geppetti is since 2002 professor of clinical pharmacology at the University of Florence and Head of the Headache Center and Clinical Pharmacology Unit of the University Hospital of Careggi-Florence.

He has been visiting professor at the University of California, San Francisco. He has been editor of the British Journal of Pharmacology and is editor of Pain, Molecular Pain, The Journal of Headache and Pain, Fundamental and Clinical Pharmacology, Journal of Molecular Neuroscience, Cough and Handbook of Experimental Pharmacology.

He has authored 275 original or review articles in peer reviewed journals and various scientific books, with 9741 citations and an Hirsch Index of 53.
He is co-founder of Pharmeste Srl, spin-off of the University of Ferrara.

return to list


Daniela Jabès, PhD

Graduated in Biological Sciences, with a PhD in Medical Microbiology at the University of Milan, Daniela did her postdoc at the Rockefeller University, NY. She has a long and documented experience in R&D of new antiinfectives, matured in Pharma and Biotech Companies.

Prior to covering the position of VP, Medical Microbiology at Biosearch Italia/Vicuron, she worked at the Nerviano Research Center (Pharmacia Corp) contributing to the discovery of several new antibiotics. In 2005 she founded NeED Pharma, where she is currently CEO. In 2007 she founded NAICONS, with the mission to re-establish R&D activities in the anti-infective field in Italy.

In 2008 she co-founded NexThera Bioscences, a Pharma company focusing on the development of anti-infectives. Daniela is co-author of more than 80 scientific publications and co-inventor of 17 patents. In 2011 she co-founded the NeED Foundation, dedicated to supporting the treatment of neglected diseases, particularly tuberculosis and malaria.

return to list


Gaetano Orsini, B.Sc.

Gaetano Orsini, from 19860 to 1984, has carried out research activities at the  pharmaceutical companies Carlo Erba and Farmitalia for the preclinical development of antiinflammatory, antidiabetic and  antidislipemic drugs.

From 1985 to 1996, as head of Protein Biochemistry Unit of Farmitalia’s Biotechnology Division he has been involved in R&D projects in the field of recombinant therapeutic proteins.
In 1997 he founded Bioter, a consulting firm which, until 2010, collaborated with small-medium biotech enterprises in the fields of recombinant enzymes and biodrugs. In 2003 he associated to Prigen, a start-up company which operates in  biotechnology and cosmeceutic comparts.

He is author of about 70 scientific papers and 15 international patents and has been involved in teaching at the University of Milan (1990-1998) and, from 2004, at the Vita-Salute Saint Raphael University of Milan.
Gaetano Orsini holds a degree in Pharmacy from the University of Milan.

return to list


Pierfausto Seneci, B.Sc.

Pierfausto Seneci is Associate Professor at the University of Milan since 2003, and acts as a consultant for a number of European SMEs, including CISI scrl – Italy and ERA Biotech – Spain.

He has more than 25 years of experience in preclinical and clinical research – CNS, antibacterials, oncology -, in project and resources’ management, in business development and fund raising, gained in pharmaceutical companies, such as Marion Merrell Dow, Glaxo Wellcome and SmithKline Beecham. He has successfully led as a CEO the Munich-based SME Sirenade Pharmaceuticals, progressing its CNS-focused pipeline and securing investments in excess of 15M €.

He is advising public and private institutions for the review of scientific projects and the support to new start-up initiatives, assisting both in the scientific – technology business case build up, and in the intangible-tangible incubation process.
Pierfausto Seneci holds a degree in Pure Chemistry from the University of Pavia.

return to list